Legal & General Group Plc Raises Position in COPT Defense Properties $CDP

Posted by Stanley Muller on Jun 1st, 2026

Legal & General Group Plc increased its holdings in COPT Defense Properties (NYSE:CDP – Free Report) by 7.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 764,942 shares of the company’s stock after purchasing an additional 53,735 shares during the period. Legal & General Group Plc’s holdings in COPT Defense Properties were worth $21,265,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Royal Bank of Canada grew its holdings in COPT Defense Properties by 12.1% in the first quarter. Royal Bank of Canada now owns 104,602 shares of the company’s stock valued at $2,853,000 after purchasing an additional 11,316 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in COPT Defense Properties by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 67,030 shares of the company’s stock worth $1,828,000 after purchasing an additional 2,931 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of COPT Defense Properties by 5.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 834,042 shares of the company’s stock valued at $22,744,000 after purchasing an additional 39,683 shares during the last quarter. Jane Street Group LLC boosted its holdings in shares of COPT Defense Properties by 152.4% in the 1st quarter. Jane Street Group LLC now owns 214,122 shares of the company’s stock valued at $5,839,000 after purchasing an additional 129,303 shares during the last quarter. Finally, Invesco Ltd. grew its stake in shares of COPT Defense Properties by 11.8% during the 2nd quarter. Invesco Ltd. now owns 758,513 shares of the company’s stock valued at $20,920,000 after buying an additional 80,153 shares during the period.

Insider Transactions at COPT Defense Properties

In related news, Director Robert L. Denton sold 3,922 shares of COPT Defense Properties stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $32.38, for a total transaction of $126,994.36. Following the sale, the director owned 3,803 shares of the company’s stock, valued at $123,141.14. The trade was a 50.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.66% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of analysts have recently commented on CDP shares. Citigroup upped their price objective on COPT Defense Properties from $29.00 to $34.00 and gave the stock a “neutral” rating in a report on Tuesday, February 10th. JPMorgan Chase & Co. upped their price target on COPT Defense Properties from $33.00 to $34.00 and gave the stock a “neutral” rating in a research note on Friday, May 15th. Weiss Ratings raised COPT Defense Properties from a “buy (b-)” rating to a “buy (b)” rating in a research note on Tuesday, April 21st. Evercore restated an “outperform” rating and issued a $38.00 price target on shares of COPT Defense Properties in a report on Tuesday, April 28th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $37.00 price objective on shares of COPT Defense Properties in a research note on Wednesday, April 29th. Five investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $34.50.

View Our Latest Analysis on CDP

COPT Defense Properties Price Performance

CDP stock opened at $32.05 on Monday. The stock has a 50-day simple moving average of $31.74 and a 200-day simple moving average of $30.82. The firm has a market cap of $3.63 billion, a P/E ratio of 23.22 and a beta of 0.79. The company has a debt-to-equity ratio of 1.63, a quick ratio of 2.85 and a current ratio of 2.85. COPT Defense Properties has a 1 year low of $26.91 and a 1 year high of $33.33.

COPT Defense Properties (NYSE:CDP – Get Free Report) last released its quarterly earnings results on Monday, April 27th. The company reported $0.34 earnings per share for the quarter, missing analysts’ consensus estimates of $0.68 by ($0.34). COPT Defense Properties had a return on equity of 10.02% and a net margin of 20.10%.The company had revenue of $200.64 million during the quarter, compared to analysts’ expectations of $185.10 million. During the same quarter in the prior year, the company earned $0.65 EPS. The firm’s revenue was up 6.8% compared to the same quarter last year. COPT Defense Properties has set its FY 2026 guidance at 2.730-2.790 EPS and its Q2 2026 guidance at 0.680-0.700 EPS. On average, equities analysts predict that COPT Defense Properties will post 2.78 earnings per share for the current fiscal year.

COPT Defense Properties Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Tuesday, June 30th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 4.0%. The ex-dividend date of this dividend is Tuesday, June 30th. COPT Defense Properties’s dividend payout ratio (DPR) is presently 92.75%.

About COPT Defense Properties

(Free Report)

COPT Defense Properties (NYSE: CDP) is a real estate investment trust organized to own, lease and manage healthcare and life science facilities serving the United States federal government, with a particular focus on Department of Defense and Veterans Affairs tenants. The company was formed in 2016 through a spin-off from Corporate Office Properties Trust, enabling it to concentrate exclusively on medical office buildings and specialized research facilities situated on or near military and federal research campuses.

The company’s portfolio comprises purpose-built, Class A medical office and outpatient specialty clinics, as well as life science laboratories.